Overview

A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Subjects With Comorbid Major Depressive Disorder and Insomnia

Status:
Terminated
Trial end date:
2020-01-17
Target enrollment:
Participant gender:
Summary
This study is a randomized, double-blind, placebo-controlled study of the safety, tolerability, and efficacy of SAGE-217 compared to placebo in adult subjects with comorbid major depressive disorder and insomnia
Phase:
Phase 3
Details
Lead Sponsor:
Sage Therapeutics